{"&cites=5867411617187961800&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Cost-containment policies in public pharmaceutical spending in the EU","url":"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2161803","authors":["G Carone","G Carone C Schwierz","G Carone C Schwierz A Xavier"],"year":2012,"numCitations":184,"pdf":"https://mpra.ub.uni-muenchen.de/42008/1/MPRA_paper_42008.pdf","citationUrl":"http://scholar.google.com/scholar?cites=13065636972614623387&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:m6DnFJp3UrUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13065636972614623387&hl=en&as_sdt=2005&sciodt=0,5","publication":"papers.ssrn.com","p":1,"exp":1596876810199},{"title":"Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for …","url":"https://www.sciencedirect.com/science/article/pii/S1098301513018111","authors":["LP Garrison Jr","LP Garrison Jr A Towse","LP Garrison Jr A Towse A Briggs","LP Garrison Jr A Towse A Briggs G de Pouvourville…"],"year":2013,"numCitations":182,"pdf":"https://www.sciencedirect.com/science/article/pii/S1098301513018111","citationUrl":"http://scholar.google.com/scholar?cites=2067565791340501145&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:mZiZ_iF4sRwJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2067565791340501145&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Value in pharmaceutical pricing","url":"https://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en","authors":["V Paris","V Paris A Belloni"],"year":2013,"numCitations":153,"pdf":"https://www.who.int/medicinedocs/documents/s21368en/s21368en.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16278589570517315611&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:GzAQe_cq6eEJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16278589570517315611&hl=en&as_sdt=2005&sciodt=0,5","publication":"oecd-ilibrary.org"},{"title":"Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study","url":"https://www.sciencedirect.com/science/article/pii/S1470204515004490","authors":["S Vogler","S Vogler A Vitry"],"year":2016,"numCitations":132,"pdf":"https://www.lesdebatspublicsdelipc.com/wp-content/uploads/2015/12/price-countries.pdf","citationUrl":"http://scholar.google.com/scholar?cites=14822251102123917904&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:UAK9gdg2s80J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14822251102123917904&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?","url":"https://www.tandfonline.com/doi/abs/10.1586/17512433.2015.990380","authors":["B Godman","B Godman RE Malmström","B Godman RE Malmström E Diogene…"],"year":2015,"numCitations":112,"pdf":"https://strathprints.strath.ac.uk/50989/6/Godman_etal_ERCP_2014_Are_new_models_needed_to_optimise_the_utilization.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10217696261251741224&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:KDa_Kp2MzI0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10217696261251741224&hl=en&as_sdt=2005&sciodt=0,5","publication":"Taylor & Francis"},{"title":"Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and …","url":"https://www.sciencedirect.com/science/article/pii/S0277953614007266","authors":["A Ferrario","A Ferrario P Kanavos"],"year":2015,"numCitations":108,"citationUrl":"http://scholar.google.com/scholar?cites=1597359749365069205&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:lXVplzr2KhYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1597359749365069205&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements …","url":"https://link.springer.com/article/10.1186/1750-1172-8-198","authors":["T Morel","T Morel F Arickx","T Morel F Arickx G Befrits","T Morel F Arickx G Befrits P Siviero…"],"year":2013,"numCitations":94,"pdf":"https://link.springer.com/article/10.1186/1750-1172-8-198","citationUrl":"http://scholar.google.com/scholar?cites=9445084379499429556&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:tH6ncTOuE4MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9445084379499429556&hl=en&as_sdt=2005&sciodt=0,5","publication":"Springer"},{"title":"Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement","url":"https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2010.1147","authors":["PJ Neumann","PJ Neumann JD Chambers","PJ Neumann JD Chambers F Simon","PJ Neumann JD Chambers F Simon LM Meckley"],"year":2011,"numCitations":89,"pdf":"https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2010.1147","citationUrl":"http://scholar.google.com/scholar?cites=16277511124980405535&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:HxXtTyBW5eEJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16277511124980405535&hl=en&as_sdt=2005&sciodt=0,5","publication":"healthaffairs.org"},{"title":"Policies for biosimilar uptake in Europe: an overview","url":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190147","authors":["E Moorkens","E Moorkens AG Vulto","E Moorkens AG Vulto I Huys","E Moorkens AG Vulto I Huys P Dylst","E Moorkens AG Vulto I Huys P Dylst B Godman…"],"year":2017,"numCitations":92,"pdf":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190147","citationUrl":"http://scholar.google.com/scholar?cites=11736999427751836745&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:SXwcVMsy4qIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11736999427751836745&hl=en&as_sdt=2005&sciodt=0,5","publication":"journals.plos.org"},{"title":"Discounts and rebates granted to public payers for medicines in European countries","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471187/","authors":["S Vogler","S Vogler N Zimmermann","S Vogler N Zimmermann C Habl…"],"year":2012,"numCitations":89,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471187/","citationUrl":"http://scholar.google.com/scholar?cites=3121680952657032052&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:dLM5fUlwUisJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3121680952657032052&hl=en&as_sdt=2005&sciodt=0,5","publication":"ncbi.nlm.nih.gov"}]}